Benefits and risks of deferiprone in iron overload in thalassaemia and other conditions: Comparison of epidemiological and therapeutic aspects with deferoxamine

Drug Safety

Volumn 26, Issue 8, 2003, Pages 553-584

  Kontoghiorghes, George J ^a   Neocleous, Katia ^a   Kolnagou, Annita ^a  

^a Postgraduate Research Institute of Science Technology Environment and Medicine Limassol   (Cyprus)

Author keywords

[No Author keywords available]

Indexed keywords

1 ALLYL 2 METHYL 3 HYDROXYPYRID 4 ONE; 1 METHYL 2 METHYLMETHOXY 6 METHYL 3 HYDROXYPYRID 4 ONE; CP 502; DEFERASIROX; DEFERIPRONE; DEFERITRIN; DEFEROXAMINE; IRON CHELATING AGENT; L1 NA11; ORPHAN DRUG; UNCLASSIFIED DRUG;

AGRANULOCYTOSIS; ALLERGIC REACTION; APLASTIC ANEMIA; ARTHRALGIA; CHELATION THERAPY; CLINICAL TRIAL; COMPARATIVE TOXICOLOGY; DRUG COST; DRUG DEGRADATION; DRUG EXCRETION; DRUG FATALITY; DRUG WITHDRAWAL; EYE TOXICITY; GASTROINTESTINAL SYMPTOM; GROWTH RETARDATION; HUMAN; IRON ABSORPTION; IRON BALANCE; IRON CHELATION; IRON KINETICS; IRON OVERLOAD; LETHAL DOSE; LEUKOPENIA; LIVER FIBROSIS; LUNG TOXICITY; MEDICAL ASSESSMENT; MUCORMYCOSIS; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; PATHOGENESIS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; TARGET ORGAN; THALASSEMIA; THROMBOCYTOPENIA; YERSINIOSIS; ZINC DEFICIENCY;

DEFEROXAMINE; ERYTHROCYTE TRANSFUSION; HUMANS; IRON CHELATING AGENTS; IRON OVERLOAD; RISK; THALASSEMIA;

EID: 0038649860     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200326080-00003     Document Type: Review

References (242)

1. Thomson AM, Rogers JT, Leedman PJ. Iron-regulatory proteins, iron-responsive elements and ferritin mRNA translation. Int J Biochem Cell Biol 1999; 31: 1139-52
2. Richardson DR, Ponka P. The molecular mechanisms of the metabolism and transport of iron in normal and neoplastic cells. Biochim Biophys Acta 1997; 1331: 1-40
3. World Health Organisation. Community control of hereditary anaemias WHO Bull 1983; 61: 63-80
4. Modell B, Berdoukas V. The clinical approach to thalassaemia. London: Grune and Stratton, 1984
5. Weatherall DJ, Glegg JB. The Thalassaemia syndromes. 3rd ed. Oxford: Blackwell Scientific Publications, 1981
6. Agarwal MB. Living with thalassaemia. Bombay: Bhalani Book Depot, 1986: 240
7. Ringborn A. Chemical analysis. In: Elving PJ, Kolthoff IM, editors. Complexation in analytical chemistry. New York: Interscience Pub, 1963: 1-374
8. Anderson WF, Hiller MC, editors. Development of iron chelators for clinical use. Bethesda, USA: National Institute of Health, 1975: 1-277
9. Martell AE. Anderson WF, Badman DG, editors. Development of iron chelators for clinical use. Amsterdam: Elsevier, 1980: 1-311
10. Kontoghiorghes GJ, editor. Oral chelation in the treatment of thalassaemia and other diseases. Drugs Today (Barc) 1992; 28 Suppl. A: 1-187
11. Kontoghiorghes GJ. Design, properties and effective use of the oral chelator L1 and other α-ketohydroxypyridines in the treatment of transfusional iron overload in thalassaemia. Ann N Y Acad Sci 1990; 612: 339-50
12. Kontoghiorghes GJ. Comparative efficacy and toxicity of desferrioxamine, deferiprone and other iron and aluminium chelating drugs. Toxicol Lett 1995; 80: 1-18
13. Barman Balfour JA, Foster RH. Deferiprone: a review of its clinical potential in iron overload in β-thalassaemia major and other transfusion dependent diseases. Drugs 1999; 58 (3): 553-78
14. Kontoghiorghes GJ, Pattichi K, Hadjigavriel M, et al. Transfusional iron overload and chelation therapy with deferoxamine and deferiprone (L1). Transfus Sci 2000; 23: 211-23
15. Kontoghiorghes GJ. Clinical use, therapeutic aspects and future potential of deferiprone in thalassaemia and other conditions of iron and other metal toxicity. Drugs Today (Barc) 2001; 37: 23-35
16. Addis A, Loebstein R, Koren G, et al. Meta-analytic review of the clinical effectiveness of oral deferiprone (L1). Eur J Clin Pharmacol 1999; 55: 1-6
17. Porter JB. A risk benefit assessment of iron chelation therapy. Drug Saf 1997; 17 (6): 407-21
18. Brown EB. Thalassaemia. Prog Clin Biol Res 1983; 121: 33-42
19. Kontoghiorghes GJ. Present status and future prospects of oral iron chelation therapy in thalassaemia and other diseases. Indian J Paediatr 1993; 60: 485-507
20. Zurlo MG, De Stefano P, Borgna-Pignatti C, et al. Survival and causes of death in thalassaemia major. Lancet 1989; II: 27-9
21. Modell B, Khan M, Darlison M. Survival in beta thalassaemia major in the UK: data from the UK thalassaemia register. Lancet 2000; 355: 2051-2
22. Kontoghiorghes GJ, Agarwal MB, Grady RW, et al. Deferiprone for thalassaemia. Lancet 2000; 356: 428-9
23. Kontoghiorghes GJ. New concepts of iron and aluminium chelation therapy with oral L1 (deferiprone) and other chelators. Analyst 1995; 120: 845-51
24. Donfrancesco A, Deb G, Domicini C, et al. Deferoxamine, cyclophosphamide, etoposide, carboplatin and thotepa (D-CE-CAT): a new cytoreductive chelation-chemotherapy regimen in patients with advanced neuroblastoma. Am J Clin Oncol 1992; 15: 319-22
25. Georgiou NA, Van der Bruggen J, Oudshoorn M, et al. Combining iron chelators with the nucleoside analog didanosine in anti-HIV therapy. Transfus Sci 2000; 23: 249-50
26. Blatt J, Taylor S, Kontoghiorghes GJ. Comparison of antineuroblastoma activity of desferrioxamine with that of oral iron chelators. Cancer Res 1989; 49: 2925-7
27. Kontoghiorghes GJ, Piga A, Hoffbrand AV. Cytotoxic and DNA inhibitory effects of iron chelators on human leukaemic cell lines. Haematol Oncol 1986; 4: 195-204
28. Simonart T, Boelaert JR, Mosselmans R, et al. Antiproliferative and apoptotic effects of iron chelators on human cervical carcinoma cells. Gynecol Oncol 2002; 85: 95-102
29. Hanauske-Abel HM, McCaffrey TA, Grady R. Protein hydroxylation inhibitors for fibroproliferative disorders. World Patent WO 9622021
30. Weinberg ED. Iron depletion: a defence against intracellular infection and neoplasm. Life Sci 1992; 50: 1289-97
31. Kontoghiorghes GJ, Weinberg ED. Iron: mammalian defence systems, mechanisms of disease and chelation therapy approaches. Blood Rev 1995; 9: 33-46
32. Douvas SG, May MH, Kolnagou A, et al. Effects on mycobacterium avium replication in normal human macrophages by deferiprone (L1) and other iron chelators. Possible implications on toxicity. Arzneimittel Forschung 2002; 52: 45-52
33. Brock JH, Liceaga J, Kontoghiotghes GJ. The effect of synthetic iron chelators on bacterial growth in human serum. FEMS Microbiol Immunol 1988; 47: 55-60
34. Lesic B, Foulon J, Carniel E. Comparison of the effects of deferiprone versus deferoxamine on growth and virulence of Yersinia enterocolitica. Antimicrob Agents Chemother 2002; 46: 1741-5
35. Heppner DG, Hallaway PE, Kontoghiorghes GJ, et al. Antimalarial properties of orally active iron chelators. Blood 1988; 72: 358-61
36. Mastrandrea S, Carvajal JL, Kaeda JS, et al. Growth inhibition of Plasmodium Falciparum by orally active iron chelators. Drugs Today (Barc) 1992; 28 Suppl. A: 25-7
37. Gordeuk VR, Thuma PE, Brittenham GM, et al. Iron chelation with desferrioxamine B in adults with asymptomatic P. Falciparum parasitemia. Blood 1992; 79: 308-12
38. Mohanty D, Ghosh K, Pathare AV, et al. Deferiprone (L1 ) as an adjuvant therapy for Plasmodium falciparum malaria. Indian J Med Res 2002; 115: 17-21
39. Kontoghiorghes GJ. Chelators affecting iron absorption in mice. Arzneimittel Forschung 1990; 40: 1332-5
40. Vreugdenhil G, Kontoghiorghes GJ, Van Eijk HG, et al. Impaired erythropoietin responsiveness to the anemia in rheumatoid arthritis: a possible inverse relationship with iron stores and effects of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one. Clin Exp Rheumatol 1991; 9: 35-40
41. Giordano N, Fioravanti A, Sancasciani S, et al. Increased storage of iron and anaemia in rheumatoid arthritis: usefulness of desferrioxamine. BMJ 1984; 289: 961-2
42. Vreughtenhil G, Kontoghiorghes GJ, Van Eijk, et al. Efficacy and safety of the oral chelator L1 in anaemic rheumatoid arthritis patients. Lancet 1989; II: 1398-9
43. Lodi R, Hart PE, Rajagopalana B, et al. Antioxidant treatment improves in vivo cardiac and skeletal muscle bioenergetics in patients with Friedreich's ataxia. Ann Neurol 2001; 49: 590-6
44. Koeppen AH, Dickson AC. Iron in the Hallervorden-Spatz syndrome. Pediatr Neurol 2001; 25: 148-55
45. Van der Kraaij AMM, Van Eijk HG, Koster JF. Prevention of postischemic cardiac injury by the orally active iron chelator 1,2-dimethyl-3-hydroxy-4-pyridone (L1) and the antioxidant (+)-cyanidanol-3. Circulation 1989; 80: 158-64
46. Korkina LG, Afanas'ev IB, Deeva IB, et al. Free radical status of blood of patients with iron overload: the effect of chelating treatment. Drugs Today (Barc) 1992; 28 Suppl. A: 137-41
47. Kontoghiorghes GJ, Bunce T, Bruckdorfer KR. Differentiation of the therapeutic and toxicological effects of iron and copper chelating drugs in relation to free radical toxicity. Toxicol Lett 1995; 78: 48-9
48. Korkina L, De Luca C, Deeva I, et al. L1 effects on reactive oxygen (ROS) and nitrogen species (RNS) release, haemoglobin oxidation, low molecular weight antioxidants, and antioxidant enzyme activities in red and white blood cells of thalassaemic patients. Transfus Sci 2000; 23: 253-4
49. Moridani MY, O'Brien PJ. Iron complexes of deferiprone and dietary plant catechols as cytoprotective superoxide radical scavengers. Biochem Pharmacol 2001; 62: 1579-85
50. Matthews AJ, Vercellotti GM, Menchaca HJ, et al. Iron and atherosclerosis: inhibition by the iron chelator deferiprone (L1). J Surg Res 1997; 73: 35-40
51. Arthur AS, Fergus AH, Lanzino G, et al. Systemic administration of the iron chelator deferiprone attenuates subarachnoid hemorrhage-induced cerebral vasospasm in the rabbit. Neurosurgery 1997; 41: 1385-91
52. Eybl V, Kotyzova D, Kolek M, et al. The influence of deferiprone (L1) and deferoxamine on iron and essential element tissue level and parameters of oxidative status in dietary iron-loaded mice. Toxicol Lett 2002; 128: 169-75
53. Jeremy JY, Kontoghiorghes GJ, Hoffbrand AV, et al. The iron chelators desferrioxamine and 1-alkyl-methyl-3-hydroxypyrid-4-ones inhibit vascular prostacyclin synthesis in vitro. Biochem J 1988; 254: 239-44
54. Barradas MA, Jeremy J, Kontoghiorghes GJ, et al. Iron chelators inhibit human platelet aggregation, thromboxane A synthesis and lipoxygenase activity. FEBS Lett 1989; 245: 105-9
55. Koning J, Palmer P, Franks GR, et al. Cardioxane-ICRF 187: towards anticancer drug specificity through selective toxicity reduction. Cancer Treat Rev 1991; 18: 1-19
56. Speyer JL, Green MD, Kramer E, et al. Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer. N Engl J Med 1988; 319: 745-52
57. Barnabe N, Zastre JA, Venkataram S, et al. Deferiprone protects against doxorubicin-induced myocyte cytotoxicity. Free Radic Biol Med 2002; 33: 266-75
58. Halliwell B, Gutteridge JMC, Cross CE Free radicals, antioxidants and human disease: where are we now? J Lab Clin Med 1992; 119: 598-620
59. Eybl V, Caisova D, Koutensky J, et al. Influence of iron chelators: 1,2-dialkyl-3-hydroxypyridin-4-ones on the lipid peroxidation and glutathione levels in the liver in mice. Arch Toxicol Suppl 1991; 14: 185-7
60. McLachlan CDR, Dalton AJ, Kruch TPA, et al. Intramuscular desferioxamine in patients with Alzheimer's disease. Lancet 1991; I: 1304-8
61. Taylor DM, Kontoghiorghes GJ. Mobilisation of plutonium and iron from transferrin and ferritin by hydroxypyridone chelators. Inorg Chim Acta 1986; 125: L35-8
62. Eybl V, Svihovcova P, Koutensky J, et al. Interaction of L1, L1NA11 and deferoxamine with gallium in vivo. Drugs Today (Barc) 1992; 29 Suppl. A: 173-5
63. Edwards DS, Christopher ER, Poirier MJ. Technetium-99m complexes with N-substituted 3-hydroxy-4-pridinones. World Patent WO 9310822
64. Niendorf HP, Alhassan A, Balzer TH, et al. Safety and risk of Gadolinium-DTPA: extended clinical experience after more than 5,000,000 applications. In: Felix R, Heshiki A, Hosten N, et al., editors. Gadopentetate dimeglumine (Gd-DTPA) Magnevist monograph. Oxford: Blackwell Science Pub, 1994: 21-31
65. Elorriaga R, Fernandez Martin JL, Menendez Fraga P, et al. Aluminium removal: short and long term preliminary results with L1 in rats. Drugs Today (Barc) 1992; 28 Suppl. A: 177-82
66. Kontoghiorghes GJ, Barr J, Baillod RA. Studies of aluminium mobilisation in renal dialysis patients using the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one. Arzneimittel Forschung 1994; 44: 522-6
67. Pashalidis I, Kontoghiorghes GJ. Molecular factors affecting the complex formation between deferiprone (L1) ans Cu(II): possible implications on efficacy and toxicity. Arzneimittel Forschung 2001; 51: 998-1003
68. Volf V, Kontoghiorghes GJ. Retention of injected plutonium and americium in mice and rats after oral treatment with DTPA, desferrioxamine and alpha-ketohydroxypyridines. Drugs Today (Barc) 1992; 28 Suppl. A: 169-72
69. Pashalidis I, Kontoghiorghes GJ. Effective complex formation in the interaction of I,2-dimethyl-3-hydroxypyrid-4-one (deferiprone or L1) with uranium (VI). J Radioanalyt Nucl Chem 1999; 242: 181-4
70. Martell AE, Motekaitis RJ, Clarke ET, et al. Comparison of the drugs used for the treatment of iron overload with drugs that have the potential for the same purpose. Drugs Today (Barc) 1992; 28 Suppl. A: 11-8
71. Llach F, Felsenfeld AJ, Coleman MK, et al. The natural course of dialysis osteomalaghia. Kidney Int 1986; 29: 74-9
72. Sedman AB, Klein LG, Merrit RJ, et al. Evidence of aluminium loading in infants receiving intravenous therapy. N Engl J Med 1985; 312: 1337-43
73. Edwardson JA. Ferrier IN, McArthur FK, et al. Alzheimer's disease and the aluminium hypothesis. In: Nicolini M, Zatta PF, Corain B, editors. Aluminium in chemistry, biology and medicine. New York: Raven Press, 1992: 85-96
74. Kurtzman NA, editor. Toxicity from aluminium and iron: recognition, treatment and prevention. Semin Nephrol 1986; 6 Suppl. 1: 1-41
75. Van Cutsem J, Boelaert JR. Effects of deferoxamine, feroxamine and iron on experimental mucormycosis (zygomycosis). Kidney Int 1989; 36: 1061-8
76. Mehta J, Singhal S, Revanker R, et al. Fatal systemic lupus erythematosus in patient taking oral iron chelator L1 [letter]. Lancet 1991; I: 298
77. Berdoukas V. Antinuclear antibodies in patients taking L1 [letter]. Lancet 1991; I: 672
78. Olivieri NF, Koren G, Freedman M, et al. Rarity of systemic lupus erythematosus after oral iron chelator L1. Lancet 1991; I: 924
79. Berdoukas V, Bentley P, Frost H, et al. Toxicity of oral iron chelator L1 [letter]. Lancet 1993; 341: 1088
80. Hershko C. Development of oral iron chelator L1. Lancet 1993; 343: 1088-9
81. Kontoghiorghes GJ, Agarwal MB, Tondury P, et al. Future of oral iron chelator deferiprone (L1). Lancet 1993; I: 1479-80
82. Kontoghiorghes GJ. Misinformation about deferiprone (L1) [letter]. Lancet 1993; II: 250
83. Kontoghiorghes GJ, Nasseri-Sina P, Goddard JG, et al. Safety of iron chelator L1. Lancet 1989; II: 457-8
84. Olivieri NF, Brittenham GM, Mclaren C, et al. Long term safety and effectiveness of iron chelation therapy with deferiprone for thalassaemia major. N Engl J Med 1998; 339: 417-23
85. Kowdly KV, Kaplan MM. Iron chelation therapy with oral deferiprone: toxicity or lack of efficacy. N Engl J Med 1998; 339: 468-9
86. Pippard MJ, Weatherall DJ. Deferiprone for thalassaemia. Lancet 2001; 356: 1444-5
87. Agarwal MB. Oral iron chelation: a review with special emphasis on Indian work on deferiprone (L1). Indian J. Pediatr 1993; 60: 509-16
88. Cohen A, Galanello R, Piga A, et al. A multi-centre safety trial of the oral iron chelator deferiprone. Ann N Y Acad Sci 1998; 850: 466-8
89. Cohen AR, Galanello R, Piga A, et al. Safety profile of the oral iron chelator deferiprone: a multicentre study. Br J Haematol 2000; 108: 305-12
90. Kontoghiorghes GJ, Agarwal MB, Tondury P, et al. Deferiprone or fatal iron toxic effects? Lancet 2001; 357: 882-3
91. Kontoghiorghes GJ. The design of orally active iron chelators for the treatment of thalassaemia [PhD thesis]. Colchester, UK: University of Essex, 1982: 1-243
92. Kontoghiorghes GJ. Method of synthesis of 1,2-dimethyl-3-hydroxypyrid-4-one. Greek patent 1003358. 2000
93. Sansville EA, Pelsach J, Horwitz SB. Effects of chelating agents and metal ions on the degradation of DNA by bleomycin. Biochemistry 1976; 17: 2740-6
94. Hannekens CH, Buring JE, Peto PR. Antioxidant vitamins - benefits not yet proved. N Engl J Med 1994; 330: 1080-1
95. Kontoghiorghes GJ, Aldouri MA, Hoffbrand AV, et al. Effective chelation of iron in β-thalassaemia with the oral chelator 1, 2-dimethyl-3-hydroxypyrid-4-one. BMJ 1987; 295: 1509-12
96. Pippard MJ, Jackson MJ, Hoffman K, et al. Iron chelation using subcutaneous infusion of diethylene triamine penta-acetic acid (DTPA). Scand J Haematol 1986; 36: 466-72
97. Pippard MJ, Callender ST, Finch CA. Ferrioxamine excretion in iron loaded man. Blood 1982; 60: 288-94
98. Kontoghiorghes GJ, Bartlett AN, Hoffbrand AV, et al. Long term trial with the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1). (I) Iron chelation and metabolic studies. Br J Haematol 1990; 76: 295-300
99. Olivieri NF, Koren G, Matsuii D, et al. Reduction of tissue iron stores and normalisation of serum ferritin during treatment with the oral iron chelator L1 in thalassaemia intermedia. Blood 1992; 79: 2741-8
100. Anderson LJ, Wonke B, Prescott E, et al. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia. Lancet 2002; 360: 516-20
101. Angellucci E, Brittenham GM, McLaren CE, et al. Hepatic iron concentration and total body iron stores in thalassaemia major. N Engl J Med 2000; 343: 327-31
102. Nielsen P, Fischer R, Engelhardt R, et al. Liver iron stores in patients with secondary haemochromatosis under iron chelation therapy with deferoxamine or deferiprone. Br J Haematol 1995; 91: 827-33
103. Mavrogeni SI, Gotsis ED, Markussis V, et al. T2 relaxation time study of iron overload in β-thalassaemia. MAGMA 1998; 6: 7-12
104. Anderson LJ, Holden S, Davis B, et al. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J 2001; 22: 2171-9
105. Breuer W, Hershko C, Cabantchik ZI. The importance of non-transferrin bound iron in disorders of iron metabolism. Transfus Sci 2000; 23: 185-92
106. Kontoghiorghes GJ, Bartlett AN, Sheppard L, et al. Oral iron chelation therapy with deferiprone (L1): monitoring of biochemical, drug and iron excretion changes. Arzneimittel Forschung 1955; 45: 65-9
107. Kontoghiorghes GJ. Iron chelation in biochemistry and medicine. In: Rice-Evans C, editor. Free radicals, oxidant stress and drug action. London: Rechelieu Press, 1982: 277-303
108. Sheppard L, Kontoghiorghes GJ. Competition between deferiprone, desferrioxamine and other chelators for iron and the effect of other metals. Arzheimittel Forschung 1993; 43: 659-63
109. De Virgilis S, Cognia M, Turco MP, et al. Depletion of trace elements and acute occular toxicity induced by desferrioxamine in patients with thalassaemia. Arch Dis Child 1988; 63: 250-5
110. Al-Refai FN, Wonke B, Wickens DG, et al. Zinc concentration in patients with iron overload receiving oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one or desferrioxamine. J Clin Pathol 1994; 47: 657-60
111. Kontoghiorghes GJ, Sheppard L, Chambers S. New synthetic approach and iron chelation studies of 1-alkyl-2-methyl-3-hydroxypyrid-4-ones. Arzneimittel Forschung 1987; 37: 1099-102
112. Allain P, Chaleil D, Mauras Y, et al. Pharmacokinetics of desferrioxamine and its aluminium chelates in patients on haemodialysis. Clin Chim Acta 1987; 170: 331-8
113. Kontoghiorghes GJ. Therapeutic, pharmacological and toxicological aspects of metals and new chelating drugs. Curr Top Mol Pharmacol 1993; 1: 189-211
114. Kontoghiorghes GJ. The study of iron mobilisation from transferrin using α-ketohydroxy heteroaromatic chelators. Biochim Biophys Acta 1986; 869: 141-6
115. Kontoghiorghes GJ. Iron mobilisation from lactoferrin by chelators at physiological pH. Biochim Biophys Acta 1986; 882: 267-70
116. Kontoghiorghes GJ, Chambers S, Hoffbrand AV. Comparative study of iron mobilisation from haemosiderin, ferritin and iron (III) precipitates by chelators. Biochem J 1987; 241: 87-92
117. Kontoghiorghes GJ. Decreased solubilisation of ferritin iron and fresh iron (III) precipitate following repeated chelator treatments. Inorg Chim Acta 1987; 138: 36-40
118. Keberle H. The biochemistry of desferrioxamine and its relation to iron metabolism. Ann N Y Acad Sci 1964; 119: 758-68
119. Lee P, Mohammed N, Marshall RD, et al. Intravenous infusion pharmacokinetics of desferrioxamine in thalassaemia patients. Drug Metab Dispos 1993; 21: 640-4
120. Evans RW, Sharma M, Ogwang W, et al. The effect of alpha-ketohydroxypyridine chelators on transferrin saturation in vitro and in vivo. Drugs Today (Barc) 1992; 28 Suppl. A: 19-23
121. Mostert LJ, Van Dorst JA, Koster JF, et al. Free radical and cytotoxic effects of chelators and their iron complexes in the hepatocyte. Free Radic Res Commun 1987; 3: 379-88
122. Brock JH, Liceaga J, Arthur HML, et al. The effect of novel 1-alkyl-3-hydroxy-2-methylpyrid-4-one chelators on uptake and release of iron from macrophages. Am J Haematol 1990; 34: 21-5
123. Weinberg ED. Cellular iron metabolism in health and disease. Drug Metab Rev 1990; 22: 531-79
124. Proper RD, Shurin SB, Nathan DG. Reassessment of the use of desferrioxamine B in iron overload. N Engl J Med 1976; 294: 1421-3
125. Cases A, Velly J, Sabater J, et al. Acute visual and auditory neurotoxicity in patients with end-stage renal disease receiving desferrioxamine. Clin Nephrol 1988; 29: 176-8
126. Tenenbein M, Kowalski S, Sienko A, et al. Pulmonary toxic effects of continous desferrioxamine administration in acute iron poisoning. Lancet 1992; I: 699-701
127. Sofroniadou K, Drossou M, Foundoulaki M, et al. Acute bone marrow aplasia associated with intravenous administration of deferoxamine (desferrioxamine). Drug Saf 1990; 5 (2): 152-4
128. Sharnetzky M, Konig R, Lamomek M, et al. Prophylaxis of systemic yersiniasis in Thalassaemia major [letter]. Lancet 1984; II: 791
129. De Sanctis V, Pinamonti A, Di Palma A, et al. Growth and development in thalassaemia major patients with severe bone lesions due to desferrioxamine. Eur J Paediatr 1996; 155: 368-72
130. Hoffbrand AV, Bartlett A, Veys PA, et al. Agranulocytosis and thrombocytopenia in a patient with Blackfan-Diamond anaemia during oral chelator trial [letter]. Lancet 1989; II: 457
131. Kontoghiorghes GJ, Bartlett AH, Hoffbrand AV. Prospects for effective oral iron chelation therapy in man with 1,2-dimethyl-3-hydroxypyrid-4-one and other alpha-ketohydroxypyridines. Prog Clin Biol Res 1989; 309: 107-14
132. Loebstein R, Diav-Citrin O, Atanackovic G, et al. Deferiprone-induced agranulocytosis: a critical review of five rechallenged cases. Clin Drug Invest 1997; 13: 345-9
133. Castriota-Scanderbeg A, Sacco M. Agranulocytosis, arthritis and systemic vasculitis in a patient receiving the oral iron chelator L1 (deferiprone). Br J Haematol 1997; 96: 254-5
134. Ceci A, Baiardi P, Felisi M, et al. The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients. Br J Haematol 2002; 118: 330-6
135. Kersten MJ, Lange R, Smeets MEP, et al. Long term treatment of transfusional iron overload with the oral iron chelator deferiprone (L1): a Dutch multicentre trial. Ann Haematol 1996; 73: 247-52
136. Bartlett AN, Hoffbrand AV, Kontoghiorghes GJ. Long-term trial with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1). Br J Haematol 1990; 76: 301-9
137. Davies SC, Marcus RE, Hungerford JL, et al. Ocular toxicity of high dose intravenous desferrioxamine. Lancet 1983; II: 181-4
138. Rahi AHS, Hungerford JL, Ahmed AI. Ocular toxicity of desferrioxamine: light microscopic histochemical and ultrastructural findings. Br J Ophthal 1986; 70: 373-81
139. Rubinstein M, Dupont P, Doppel JP, et al. Ocular toxicity of desferrioxamine. Lancet 1985; I: 817-8
140. Borgna-Pignatti C, De Stefano P, Broglia AM. Visual loss in patient on high dose subcutaneous desferrioxamine. Lancet 1984; I: 68
141. Agarwal MB, Gupta SS, Viswanathan C, et al. Long term assessment of efficacy and toxicity of L1 (1,2-dimethyl-3-hydroxypyrid-4-one) in transfusion dependent thalassaemia: Indian trial. Drugs Today (Barc) 1992; 28 Suppl. A: 107-14
142. Berkovitch M, Laxer RM, Inman R, et al. Arthropathy in thalassaemia patients receiving deferiprone. Lancet 1994; 343: 1471-2
143. Guerin A, London G, Marchais S, et al. M. Acute deafness and desferrioxamine. Lancet 1985; II: 39-40
144. Roger SD, Stewart JH, Harris DCU. Desferrioxamine enhances the haemopoietic response to erythropoietin but adverse events are common. Nephron 1991; 58: 33-6
145. Polson RJ, Jawed A, Bomford A, et al. Treatment of rheumatoid arthritis with desferrioxamine: relation between stores of iron before treatment and side effects. Br Med J (Clin Res Ed) 1985; 291: 448
146. Bentur Y, Koren G, Tegoro A, et al. Comparison of deferoxamine pharmacokinetics between asymptomatic thalassemic children and those exhibiting severe neurotoxicity. Clin Pharmacol Ther 1990; 47: 478-82
147. Blake DR, Winyard P, Lunec J, et al. Cerebral and ocular toxicity induced by desferrioxamine. Q J Med 1985; 56: 345-55
148. Freedman MH, Grisaru D, Olivieri N, et al. Pulmonary syndrome in patients with thalassaemia major receiving intravenous deferoxamine infusions. Am J Dis Child 1990; 144: 565-9
149. Tondury P, Zimmerman A, Nielsen P, et al. Liver iron fibrosis during long-term treatment with deferiprone in Swiss thalassaemic patients. Br J Haematol 1998; 101: 413-5
150. Wanless IR, Sweeney G, Dhillon AP, et al. Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia. Blood 2002; 100: 1566-9
151. De Virgidis S, Cognie M, Frau F, et al. Deferoxamine-induced growth retardation in patients with thalassaemia major. J Pediatr 1988; 113: 661-9
152. De Sanctis V, Atti C, Banim P, et al. Growth in thalassaemia major. Acta Med Auxal 1991; 23: 29-36
153. Robins-Browne RM, Pipic JK. Desferrioxamine and systemic yersiniosis [letter]. Lancet 1983; II: 1372
154. Scharnetzky M, Konig R, Lakomek M, et al. Prophylaxis of systemic yersiniosis in thalassaemia major [letter]. Lancet 1984: I: 791
155. Gordts B, Rummens E, De Meirleir L, et al. Yersinia pseudoturberculosis septicaemia in thalassaemia major. Lancet 1984; I: 41-2
156. Kelly D, Price E, Wright V, et al. Yersinia and iron overload. BMJ 1986; 292: 413
157. Del Vecchio GC, Schettini F, Placente L, et al. Effects of deferiprone on immune status and cytokine pattern in thalassaemia major. Acta Haematol 2002; 108: 144-9
158. Aydinok Y, Nisli G, Kavakli K, et al. Sequential use of L1 and desferrioxamine in primary school children with thalassaemia major in Turkey. Acta Haematol 1999; 102: 17-21
159. Van Cutsem J, Boelaert JR. Effects of deferoxamine, feroxamine and iron on experimental mucormycosis (zygomycosis). Kidney Int 1989; 36: 1061-8
160. Walker JA, Sherman RA, Eisinger RP. Thrombocytopenia associated with intravenous desferrioxamine. Am J Kidney Dis 1985; 6: 254-6
161. Nebeker HG, Milliner DS, Ott SA, et al. Aluminium-related osteomalagia: clinical response to desferrioxamine [abstract]. Kidney Int 1984; 25: 173
162. Romeo MA, Di Gregorio F, Schiliro G. Allergy to desferrioxamine. J Inherit. Metab Dis 1984; 7: 121
163. Athanasiou A, Shepp MA, Necheles TF. Anaphylactic reaction to desferrioxamine [letter]. Lancet 1977; II: 616
164. Bousquet J, Navarpo M, Robert G, et al. Rapid desensitisation for desferrioxamine anaphylactic reactions. Lancet 1983; II: 859-60
165. Miller KB, Rosenwasser LJ, Bessette JA, et al. Rapid desensitisation for desferrioxamine anaphylactic reaction [letter]. Lancet 1987; I: 1059
166. Batey R, Scott J, Jain S, et al. Acute renal insufficiency occurring during intravenous desferrioxamine therapy. Scand J Haematol 1979; 22: 277-9
167. Wayne AS, Rosenblum ND, Sallan D, et al. Renal abnormalities in patients with β-thalassaemia major treated with chronic subcutaneous deferoxamine [abstract]. Blood 1993; 82 Suppl. 1: 476a
168. Kontoghiorghes GJ. Orally active α-ketohydroxypyridine iron chelators: effects on iron and other metal mobilisations. Acta Haematol 1987; 78: 212-6
169. Klebanoff SJ, Waltersdorph AM, Michel BR, et al. Oxygen-based free radical generation by ferrous ions and desferioxamine. J Biol Chem 1989; 254: 19765-71
170. Ganeshaguru K, Lally KM, Piga A, et al. Cytotoxic mechanisms of iron chelators. Drugs Today (Barc) 1992; 28 Suppl. A: 29-34
171. Lederman HM, Cohen A, Lee JWW, et al. Deferrioxaraine: a reversible S-phase inhibitor of human lymphocyte proliferation. Blood 1984; 64: 748-53
172. Summers MR, Jacobs A, Tudway D, et al. Studies in desferrioxamine and ferrioxamine iron metabolism in normal and iron loaded subjects. Br J Haematol 1979; 42: 547-55
173. Marcus RE, Davies SG, Bantock HM, et al. Desferrioxamine to improve cardiac function in iron-overloaded patients with thalassaemia major. Lancet 1984; I: 392-3
174. Cohen A, Martin M, Schwartz E. Depletion of excessive liver iron stores with desferrioxamine. Br J Haematol 1984; 58: 369-73
175. Kontoghiorghes GJ, Marcus RE, Huehns ER. Desferrioxamine suppositories [letter]. Lancet 1983; II: 454
176. Callender ST, Weatherall DJ. Iron chelation with oral desferrioxamine [letter]. Lancet 1980; II: 689
177. Kontoghiorghes GJ. L1 (1,2-dimethyl-3-hydroxypyrid-4-one). Drugs Future 1988; 13: 413-5
178. Kontoghiorghes GJ, Piga A, Hoffbrand A. Cytotoxic effects of the lipophilic iron chelator omadine. FEBS Lett 1986; 204: 208-12
179. Kontoghiorghes GJ, Goddard JG, Bartlett AN, et al. Pharmacokinetic studies in humans with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one. Clin Pharmacol Ther 1990; 48: 255-61
180. Sheppard L, Kontoghiorghes GJ. Synthesis and metabolism of L1 and other novel alpha-ketohydroxypyridine iron chelators and their metal complexes. Drugs Today (Barc) 1992; 28 Suppl. A: 3-10
181. Matsui D, Klein J, Hermann C, et al. Relationship between the pharmacokinetics and iron excretion pharmacodynamics of the new oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one in patients with thalassaemia. Clin Pharmacol Ther 1991; 50: 294-8
182. 59Fe-labelling technique. Drugs Today (Barc) 1992; 28 Suppl. A: 45-53
183. Diav-Citrin O, Atanackovic G, Koren G. An investigation into variability in the therapeutic response to deferiprone in patients with thalassaemia major. Ther Drug Monit 1999; 21: 74-81
184. Kontoghiorghes GJ, Aldouri MA, Sheppard LN, et al. 1,2-Dimethyl-3-hydroxypyrid-4-one, on orally active chelator for the treatment of transfusional iron overload. Lancet 1987; I: 1294-5
185. Olivieri NF, Koren G, Hermann C, et al. Comparison of oral iron chelator L1 and desferrioxamine in iron loaded patients. Lancet 1990; II: 1275-9
186. Agarwal MB, Gupta SS, Viswanathan C, et al. Long term assessment of efficacy and safety of L1, an oral iron chelator in transfusion dependent thalassaemia: Indian trial. Br J Haematol 1992; 82: 460-6
187. Tondury P, Kontoghiorghes GJ, Ridolfi-Luthy R, et al. L1 (1,2-dimethyl-3-hydroxypyrid-4-one) for oral iron chelation in patients with B -thalassaemia major. Br J Haematol. 1990; 76: 550-3
188. Goudsmit R, Kersten MJ. Long term treatment of transfusion hemosiderosis with the oral iron chelator L1. Drugs Today (Barc) 1992; 28 Suppl. A: 133-5
189. Jaeger M, Aul C, Sohngen D, et al. Iron overload in polytransfused patients with MDS: use of L1 for oral iron chelation. Drugs Today (Barc) 1992; 28 Suppl. A: 143-7
190. Carnelli V, Spadaro C, Stefano V, et al. L1 efficacy and toxicity in poorly compliant and for refractory to desferrioxamine thalassaemia patients: interim report. Drugs Today (Barc) 1992; 28 Suppl. A: 119-21
191. Collins AF, Fassos FF, Stobie S, et al. Iron balance and dose response studies of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron loaded patients with sickle cell disease. Blood 1994; 83: 2329-3
192. Rombos Y, Tzanetea R, Konstantopoulos K, et al. Chelation therapy in patients with thalassaemia using the orally active iron chelator deferiprone (L1). Haematologica 2000; 85: 115-7
193. Diav-Citrin O, Koren G. Oral iron chelation with deferiprone. Pediatr Clin North Am 1997; 44: 235-47
194. Mazza P, Amurri B, Lazzari G, et al. Oral iron chelating therapy: a single centre interim report on deferiprone (L1) in thalassemia. Haematologica 1998; 83: 496-501
195. Berdoukas V, Bohane T, Eagle C, et al. The Sydney children's hospital experience with the oral iron chelator deferiprone (L1). Transfus Sci 2000; 23: 239-40
196. Dresow B, Fischer R, Nielsen P, et al. Effect of oral iron chetator L1 in iron absorption in man. Ann N Y Acad Sci 1998; 850: 466-8
197. Kontoghiorghes GJ. New orally active iron chelators. Lancet 1985; II: 817
198. Kontoghiorghes GJ, Bartlett AN, Hoffbrand AV, et al. Intensive chelation and iron balance studies using oral 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in man [abstract]. Br J Haematol 1990; 74 Suppl. 1: 10
199. Ciba Report on Desferal. Adverse Drug Reaction Centre. Information No.2. 1965 Oct: 1-38
200. Pope E, Berkovitch M, Klein J, et al. Salivary measurement of deferiprone concentrations and correlation with serum levels. Ther Drug Monit 1997; 19: 95-7
201. Taher A, Chamoun FM, Koussa S, et al. Efficacy and side effects of deferiprone (L1) in thalassaemia patients not compliant with desferrioxamine. Acta Haematol 1999; 101: 173-7
202. Zahet L, Murad FH, Alameddine R, et al. Effect of iron chelation therapy with deferiprone (L1) on the psychosocial status of thalassaemia patients. Haematologia 2002; 31: 333-9
203. Al-Refai FN, Wonke B, Hoffbrand AV, et al. Efficacy and possible adverse effects of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in thalassaemia major. Blood 1992; 80: 593-9
204. Cermak J, Brabec V. Treatment of iron overload states with oral administration of the chelator L1. Vnitr Lek 1994; 40: 586-90
205. Adhikari D, Roy TB, Biswas A, et al. Efficacy and safety of oral iron chelating agent deferiprone in beta-thalassaemia and hemoglobin E-beta thalassemia. Indian Pediatr 1995; 32: 855-61
206. Lucas GN, Perera BJ, Foneka EA, et al. A trial of deferiprone in transfusion-dependent iron overloaded children. Ceylon Med J 2000; 45: 71-4
207. Uetrecht JP. Drug metabolism by leukocytes and its role in drug-induced Lupus and other idiosyncratic drug reactions. Toxicology 1990; 20: 213-35
208. Fugata S, Murakami Y, Kuma K, et al. G-CSF levels during spontaneous recovery from drug-induced agranulocytosis [letter]. Lancet 1993; 342; 1495: 242
209. Al-Refai FN, Wonke B, Hoffbrand AV. Deferiprone-associated myelotoxicity. Eur J Haematol 1994; 53: 298-301
210. Kontoghiorghes GJ. Advances in oral iron chelation in man. Int J Haematol 1992; 55: 27-38
211. Kontoghiorghes GJ. Dose response studies using desferrioxamine and orally active chelators in a mouse model. Scand J Haematol 1986; 37: 63-70
212. Kontoghiorghes GJ, Hoffbrand AV. Orally active α-ketohydroxy pyridine iron chelators intended for clinical use: in vivo studies in rabbits. Br J Haematol 1986; 62: 607-13
213. Wonke B, Wright C, Hoffbrand AV. Combined therapy with deferiprone and deferoxamine. Br J Haematol 1998; 103: 361-4
214. Kontoghiorghes GJ, Kolnagou A. Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility. Lancet 2003; 361: 184
215. Maggio A, D'Amico G, Morabito A, et al. Deferiprone versus deferoxamine in patients with thalassaemia major: a randomised clinical trial. Blood Cells Mol Dis 2002; 28: 196-208
216. Panayi GS, HustonG, Shah RR. Deficient sulphoxidation status in D-penicillamine toxicity. Lancet 1983; I: 414
217. Stobie S, Tyberg J, Matsui D, et al. Comparison of the pharmacokinetics of 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in healty volunteers, with and without co-administration of ferrous sulfate, to thalassaemia patients. Int J Clin Pharmacol Ther Toxicol 1993; 31: 602-5
218. Kontoghiorghes GJ, Barr J, Baillod RA. Aluminium mobilisation in renal dialysis patients using the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1). Drugs Today (Barc) 1992; 28 Suppl. A: 183-7
219. Thuma PE, Olivieri NF, Mabeza GF, et al. Assessment of the effect of the oral iron chelator deferiprone on asymptomatic Plasmodium falciparum parasitaemia in humans. Am J Trop Med Hyg 1998; 58: 358-64
220. Kontoghiorghes GK, Jackson MI, Lunec J. In vitro screening of iron chelators using models of free radical damage. Free Radic Res Commun 1986; 2: 115-24
221. Ling G, Tirosh R, Pinson A, et al. Role of iron in the potentiation of anthracycline cardiotoxicity: identification of heart cell mitochondria as major site of iron-anthracycline interactions. J Lab Clin Med 1996; 127: 272-8
222. Forsbeck K, Nillson K, Kontoghiorghes GJ. Variation in iron accumulation, transferrin membrane binding and DNA synthesis in the K562 and U937 cell lines induced by chelators and their iron complexes. Eur J Haematol 1987; 39: 318-25
223. Voest EE, Vreugdenhil G, Marx JJM. Iron-chelating agents in non-iron overload conditions. Ann Intern Med 1994; 120: 490-9
224. Sadrzadeh SMH, Nanji AA, Price PL. The oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one reduces hepatic-free iron, lipid peroxidation and fat accumulation in chronically ethanol-fed rats. J Pharmacol Exp Ther 1994; 269: 632-6
225. Fredenburg AM, Sethi RK, Allen DD, et al. The pharmacokinetics and blood-brain barrier permeation of the chelators 1,2-dimethyl, 1,2-diethyl, and 1-[ethan-l'ol]-2-methyl-3-hydroxypyrid-4-one in the rat. Toxicology 1996; 108 (3): 191-9
226. Kontoghiorghes GJ, May A. Uptake and intracellular distribution of iron from transferrin and chelators in erythroid cells. Biol Met 1990; 3: 183-7
227. Motekaitis R. J, Martell AE. Stabilities of the iron (III) chelates of 1,2-dimethyl-3-hydroxy-4-pyridinone and related ligands. Inorg Chim Acta 1991; 183: 71-80
228. Borgna-Pignatti C, Cohen A. Evaluation of a new method of administration of the iron chelating agent deferoxamine. J Pediatr 1997; 130: 86-8
229. Hirase N, Abe Y, Salamura S, et al. Anemia and neutropenia in a case of copper deficiency: role of copper in normal hematopoiesis. Acta Haematol 1992; 87: 195-7
230. Higuchi S, Higashi A, Nahamura T, et al. Anti-neutrophil antibodies in patients with nutritional copper deficiency. Eur J Paediatr 1991; 150: 327-30
231. Young GAR, Vincent PC. Drug induced agranulocytosis. Clin Haematol 1980; 9: 483-504
232. Uetrecht JP. Idiosyncratic drug reaction: possible role of reactive metabolites generated by leukocytes. Pharm Res 1989; 6: 265-73
233. Kontoghiorghes GJ. L1NA11. -Altyl-2-methyl-3-hydroxypyrid-4-one. Drugs Future 1990; 15: 230-2
234. Nortey P, Barr J, Matsakis M, et al. Effect on iron excretion and animal toxicology of L1 and other alpha-ketohydroxypyridine chelators. Drugs Today (Barc) 1992; 28 Suppl. A: 81-8
235. Goddard JG, Kontoghiorghes GJ. Development of an HPLC analytical method for orally administered 1-substituted-2-alkyl-3-hydroxypyrid-4-one iron chelators in biological fluids. Clin Chem 1990; 36: 5-8
236. Spino M, Yang J. Pharmacokinetics and whole body distribution of CP 502: a hydroxypyridinone second generation oral iron chelator [abstract book]. 12th International Conference on Oral Chelation (ICOC); 2002 Jul 4-7: Santorini Hellas 2002, 83-4
237. Alberti A. ICL 670: update on the clinical development of this new oral iron chelator [abstract book]. 12th International Conference on Oral Chelation (ICOC); 2002 Jul 4-7: Santorini, Hellas 2002, 85-6
238. Galanello R, Cappellini MD, Piga A, et al. Update on the effects of ICL 670, a novel tridentate oral iron chelator, on liver iron concentration in patients with transfusion dependent iron overload [abstract book]. 12th International Conference on Oral Chelation (ICOC); 2002 Jul 4-7: Santorini, Hellas 2002, 90-1
239. Marquis JK, Bree M, Appelqvist T. Bioavailability and pharmacokinetic properties of GT56-252, a novel orally available iron chelator [abstract book]. 12th International Conference on Oral Chelation (ICOC); 2002 Jul 4-7: Santorini, Hellas. 2002: 113 (P1)
240. Marquis JK, Aoude-Dagher R, Guillaumat PO. Pharmaology and toxicology of GT56-252, a novel orally available iron chelator [abstract book]. 12th International Conference on Oral Chelation (ICOC); 2002 Jul 4-7: Santorini, Hellas 2002, 113 (P2)
241. Kontoghiorghes GJ, Sheppard L. Simple synthesis of the potent iron chelators 1-alkyl-3-hydroxy-2-methylpyrid-4-ones. Inorg Chim Acta 1987; 136: L11-2
242. Kontoghiorghes GJ. Oral iron chelation is here. BMJ 1991; 303: 1279-80